Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis

Extended lymph node removal does not benefit patients with clinically localised muscle-invasive bladder cancer

Dostarlimab chemo combination for primary advanced or recurrent endometrial cancer

2L triple metronomic chemo shows more efficacy in comparison to systemic therapy for head and neck cancer

ASCO 2023: Breast cancer research highlights

Ciltacabtagene autoleucel greatly reduces risk of disease progression in lenalidomide-refractory MM

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity

ASCO 2023: Head and neck highlights

Cabozantinib with nivolumab/ipilimumab shows superior efficacy compared to cabozantinib alone in soft tissue sarcoma

Elranatamab shows efficacy in RRMM with prior BCMA-directed treatment

Nivolumab-AVD reduces the risk of disease progression compared to brentuximab vedotin-AVD in advanced Hodgkin lymphoma

HCC: Improvement in RFS for atezolizumab plus bevacizumab vs active surveillance without compromising QoL